Pembrolizumab Treatment for Advanced Tumors

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Recruiting Phase 3 Interventional Study
Solid Tumors Hematologic Malignancies
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
3,500 (estimated)
Sponsor
Merck Sharp & Dohme LLC · Industry
Who this trial is looking for

This trial is looking for patients with advanced tumors who have been treated with pembrolizumab or a similar treatment in previous studies. Participants will receive additional doses of pembrolizumab or related therapies over a few months.

Are You a Good Fit for This Trial?
Rules you out Active autoimmune diseaseSevere hypersensitivity to pembrolizumabActive central nervous system metastases

You may be able to join if

  • I have been treated in a parent study with pembrolizumab.
  • I am currently receiving pembrolizumab or related treatments.
  • I have an ECOG performance status of 0 or 1.
  • I have good organ function.
  • I have resolved any treatment side effects to Grade 1 or less.
  • I am not pregnant or breastfeeding.
  • If I can get pregnant, I agree to use contraception during the study.
  • I have not received other anticancer treatments since my last dose.

You may not be able to join if

  • I have severe hypersensitivity to pembrolizumab.
  • I received a live vaccine within the last 30 days.
  • I have a diagnosis of immunodeficiency.
  • I have another cancer that needs active treatment.
  • I have known central nervous system metastases.
  • I have an active autoimmune disease requiring treatment.
  • I have a history of severe pneumonitis.
  • I am pregnant or planning to become pregnant.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one o…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Treated on the parent pembrolizumab studies established by the Sponsor as MK-3475-587 ready. * Currently receiving pembrolizumab, pembrolizumab based combinations or lenvatinib from parent studies or in a follow-up phase. Additional eligibility criteria for participants who e…
Contacts

Toll Free Number

1-888-577-8839

Trialsites@msd.com

CONTACT